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Unlike HTLV-1, HTLV-2 does not induce leukemia and
has been tentatively associated with an HTLV-1-associated
myelopathy-like disorder. It has been reported that
HTLV-2/HIV-1 co-infected patients progress less rapidly
to AIDS than HIV-1-infected individuals. Tax2 has been
suggested to mediate this protective state by inducing
MIP-1a expression and blocking HIV-1 infection. As cells
from HTLV-2-infected individuals mainly express Anti-
sense Protein 2 (APH-2), our objective was to determine if
this protein might also intervene in controlling HIV-1
replication in dually infected individuals. Using Jurkat
cells, we first demonstrated that both APH-2 and HBZ,
the HTLV-1 analogue, equally induced MIP-1a in unsti-
mulated and stimulated Jurkat T cells. To assess if APH-2
might directly affect HIV-1 replication, a full length luci-
ferase-expressing proviral DNA was tested in Jurkat cells.
Surprisingly, upon co-transfection with an APH-2 expres-
sion vector, an increase in luciferase activity was observed,
while HBZ expression rather led to reduced reporter gene
expression. Western blot analyses and ELISA assay further
indicated that HIV-1 p24 levels were more important in
APH-2-expressing cells. To determine if APH-2 was
directly modulating HIV-1 LTR activity, both NF-B and
NFAT were tested in stimulated Jurkat cells. Unexpect-
edly, HBZ and APH-2 inhibited NF-B and NFAT activa-
tion, albeit at different extent. In addition, LTR activation
was also inhibited by both antisense proteins although
APH-2 had a more modest effect. Our results thus high-
light the complex interplay between HTLV antisense tran-
script-encoded proteins and HIV-1 expression and further
studies will be required to determine the potential impact
of APH-2 in HTLV-2/HIV-1-infected individuals.
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